US Oncology Research Plays an Important Role in the Clinical Development for NERLYNX ™ (Neratinib) Tablets

The Woodlands, Texas (September 12, 2017) — Early-stage breast cancer patients with HER2-positive tumors now have a promising new anti-HER2 treatment option in the extended adjuvant setting, thanks in large part to the efforts and expertise of US Oncology Research and McKesson Specialty Health. US O...
Source: McKesson News - Category: Information Technology Source Type: news